A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Eptinezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms PROMISE 1
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 26 Feb 2018 According to an Alder Biopharmaceuticals media release, twelve month data from this trial is expected in 1H 2018.
    • 10 Sep 2017 Results of this trial and 2 other trials (refer CTP: 228412, 250744) were presented at the 2017 International Headache Society
    • 07 Sep 2017 Data from this trial will be presented at the 18th Congress of the International Headache Society (IHC) 2017, according to an Alder Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top